SNY - Sanofi says Sarclisa improves progression-free survival in some multiple myeloma patients
2024-06-03 18:42:13 ET
More on Sanofi
- Sanofi Q1: Wait And See For Now (Downgrade)
- Sanofi: Q1 Earnings Reflect Growth And Strategic Acquisitions (Rating Upgrade)
- Sanofi 2024 Q1 - Results - Earnings Call Presentation
- Regeneron/ Sanofi say FDA has delayed Dupixent COPD label
- Sanofi's Sarclisa gets accepted for FDA priority review for treatment of multiple myeloma